medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-1-44-48medalphabet-1951Research ArticleКОМОРБИДНЫЕ СОСТОЯНИЯCOMORBIDITYУровни высокочувствительного C-реактивного белка у лиц молодого и среднего возраста и их связь с артериальной гипертензиейLevels of high‑sensitivity C‑reactive protein in young and middle‑aged individuals and their association with hypertensionhttps://orcid.org/0000-0003-0491-8823ПоляковаО. А.PolyakovaO. A.

Полякова Ольга Александровна, аспирант кафедры терапии и полиморбидной патологии

Москва

Polyakova Olga A.

Moscow

docpolyakova.olga@gmail.comhttps://orcid.org/0000-0001-8364-7472КириченкоА. А.KirichenkoA. A.

Кириченко Андрей Аполлонович, д. м. н., проф., проф. кафедры терапии и полиморбидной патологии

Москва

Kirichenko Andrey A.

Moscow

andrey.apollonovich@yandex.ruhttps://orcid.org/0000-0002-9321-3026БородинИ. А.BorodinI. A.

Бородин Игорь Анатольевич, начальник

Москва

Borodin Igor A.

Moscow

borodin@gtm.gazprom.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy for Continuing Professional EducationRussian FederationЦентр диагностики и реабилитации – филиал ООО «Газпром Трансгаз Москва»РоссияCentre for Diagnostics and Rehabilitation – a Subsidiary of Gazprom Transgaz MoscowRussian Federation20210904202101Коморбидные состояния (1)4448Copyright © Полякова О.А., Кириченко А.А., Бородин И.А., 20212021Полякова О.А., Кириченко А.А., Бородин И.А.Polyakova O.A., Kirichenko A.A., Borodin I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1951

Актуальность. Хроническое системное воспаление играет одну из ключевых ролей в развитии сердечно-сосудистых заболеваний. Тем не менее причинно-следственная связь между воспалением и артериальной гипертензией (АГ) до конца не определена.Цель исследования. Оценить уровни высокочувствительного С-реактивного белка (вч-СРБ) у лиц молодого и среднего возраста и их связь с АГ. Материалы и методы. Обследованы 427 пациентов в возрасте 30–55 лет (41 [35; 48] год), проходящих периодический медицинский осмотр на базе Центра диагностики и реабилитации ООО «Газпром Трансгаз Москва» с ноября 2018 по февраль 2020 года. 169 пациентов были оценены в динамике через 12 месяцев. Пациенты с наличием острого воспалительного заболевания или обострением хронического, принимающие гиполипидемическую, противовоспалительную, гормонально-заместительную терапию, исключались из исследования. Уровень вч-СРБ определяли иммунотурбодиметрическим методом с усилением на латексе, с нижним пределом обнаружения 0,1 мг/л. Статистическую обработку результатов осуществляли в программе Statistica 10. Различия считались статистически значимыми при p < 0,05.Результаты. Среди лиц молодого и среднего возраста повышение уровня вч-СРБ ≥ 2 мг/л было обнаружено у 26,9 % участников исследования. Концентрации вч-СРБ статистически значимо коррелировали с индексом массы тела (r = 0,53; p < 0,05) и уровнем систолического артериального давления (r = 0,28; p < 0,05). Частота выявления АГ у лиц с вч-СРБ ≥ 2 мг/л была выше, чем у лиц с нормальными уровнями маркера (65,2 против 40,1 %; р = 0,000004). Между повышением уровня вч-СРБ и АГ имелась статистически значимая связь (ОШ = 2,8; 95 % ДИ: 1,8–4,4; р = 0,000004).Заключение. Полученные данные указывают на то, что у лиц молодого и среднего возраста повышенный уровень вч-СРБ ассоциирован с АГ, а также позволяют предположить, что хроническое системное воспаление является фактором, способствующим развитию АГ.

Background. Chronic systemic inflammation plays a key role in the development of cardiovascular disease. However, the causal relationship between inflammation and arterial hypertension (AH) is not fully determined.Objective. To assess the levels of high-sensitivity С-reactive protein (hs-CRP) in young and middle-aged individuals and their association with АН. Materials and methods. The study involved 427 patients aged 30 to 55 years (41 [35; 48] years) undergoing a periodic medical examination on the basis of Gazprom Transgaz Moscow’s Centre for Diagnostics and Rehabilitation from November 2018 to February 2020. 169 patients were evaluated in dynamics after a year. Patients with acute inflammatory disease or chronic exacerbation, taking hypolipidemic, anti-inflammatory, hormone replacement therapy were excluded from the study. The hs-CRP level was determined by an immunoturbodimetric method with latex gain, with a lower detection limit of 0.1 mg/l. Statistical processing of the results was carried out in Statistica 10 program. Differences were considered statistically significant at p < 0.05.Results. Among young and middle-aged individuals increase in the level of hs-CRP ≥ 2 mg/l was found in 26.9 % of participants of the research. Protein concentrations were most significantly associated with body mass index (r = 0.53; p < 0.05) and systolic blood pressure (r = 0.28; p < 0.05). Persons with hs-CRP ≥ 2 mg/l had a frequency of identification of AH above, then at persons with normal levels of a marker (65.2 against 40.1 %; р = 0.000004). There was a statistically significant association between an increase in the level of hs-CRP and hypertension (OR = 2.8; 95 % CI: 1.8–4.4; p = 0.000004).Conclusions. The findings indicate that elevated hs-CRP levels are associated with AH in young and middle-aged individuals, and also suggest that chronic systemic inflammation is an independent contributor to the development of AH.

высокочувствительный С-реактивный белокС-реактивный белокартериальная гипертензиясердечно-сосудистые заболеваниявоспалениеhigh-sensitivity C-reactive proteinC-reactive proteinarterial hypertensioncardiovascular diseasesinflammationReferencesКардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; (6): 7–122. https://doi.org/10.15829/1560–4071–2018–6–7–122Cardiovascular Prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018; (6): 7–122 (In Russ.) https://doi.org/10.15829/1560–4071–2018–6–7–122Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25 (3): 3786. https://doi.org/10.15829/1560–4071–2020–3–3786Arterial hypertension in adults. Clinical Guidelines 2020. Russian Journal of Cardiology. 2020; 25 (3): 3786 (In Russ.). https://doi.org/10.15829/1560–4071–2020–3–3786Баланова Ю. А., Шальнова С. А., Имаева А. Э., и др. от имени участников исследования ЭССЕ-РФ-2. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии. 2019; 15 (4): 450–466. https://doi.org/10.20996/1819–6446–2019–15–4–450–466Prevalence of arterial hypertension, treatment coverage and its effectiveness in the Russian Federation (data from the observational study ESSE-RF-2). Rational Pharmacotherapy in Cardiology. 2019; 15 (4): 450–466. (In Russ.) https://doi.org/10.20996/1819–6446–2019–15–4–450–466Xiao L, Harrison DG. Inflammation in Hypertension. Can J Cardiol. 2020; 36 (5): 635–647. https://doi.org/10.1016/j.cjca.2020.01.013Xiao L, Harrison DG. Inflammation in Hypertension. Can J Cardiol. 2020; 36 (5): 635–647. https://doi.org/10.1016/j.cjca.2020.01.013Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J Exp Med. 2018; 215: 21–33. https://doi.org/10.1084/jem.20171773Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension. J Exp Med. 2018; 215: 21–33. https://doi.org/10.1084/jem.20171773Barhoumi T, Fraulob-Aquino JC, Mian MOR, et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovasc Res. 2017; 113: 1753–62. https://doi.org/10.1093/cvr/cvx115Barhoumi T, Fraulob-Aquino JC, Mian MOR, et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovasc Res. 2017; 113: 1753–62. https://doi.org/10.1093/cvr/cvx115Mikolajczyk TP, Nosalski R, Szczepaniak P, et al. Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension. FASEB J. 2016; 30: 1987–99. https://doi.org/10.1096/fj.201500088RMikolajczyk TP, Nosalski R, Szczepaniak P, et al. Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension. FASEB J. 2016; 30: 1987–99. https://doi.org/10.1096/fj.201500088RChan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med .2020; 217: e20190314. https://doi.org/10.1084/jem.20190314Chan AH, Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. J Exp Med .2020; 217: e20190314. https://doi.org/10.1084/jem.20190314Loperena R, Harrison DG. Oxidative stress and hypertensive diseases. Med Clin North Am. 2017; 101: 169–93. https://doi.org/10.1016/j.mcna.2016.08.004Loperena R, Harrison DG. Oxidative stress and hypertensive diseases. Med Clin North Am. 2017; 101: 169–93. https://doi.org/10.1016/j.mcna.2016.08.004Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet. 2010; 375: 132–140. https://doi.org/10.1016/S0140–6736(09)61717–7Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet. 2010; 375: 132–140. https://doi.org/10.1016/S0140–6736(09)61717–7Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003; 290 (22): 2945–51. https://doi.org/10.1001/jama.290.22.2945Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003; 290 (22): 2945–51. https://doi.org/10.1001/jama.290.22.2945Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association be tween inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19 (2): 149–54. https://doi.org/10.1038/sj.jhh.1001785Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association be tween inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19 (2): 149–54. https://doi.org/10.1038/sj.jhh.1001785Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39 (33): 3021–3104. https://doi.org/10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39 (33): 3021–3104. https://doi.org/10.1093/eurheartj/ehy339Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Har monizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120 (16): 1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Har monizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120 (16): 1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 74: 1376–414. https://doi.org/10.1016/j.jacc.2019.03.009Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 74: 1376–414. https://doi.org/10.1016/j.jacc.2019.03.009Pearson TA, Mensah GA, Alexander RW, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardio vascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28; 107 (3): 499–511. https://doi.org/10.1161/01.cir.0000052939.59093.45Pearson TA, Mensah GA, Alexander RW, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardio vascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28; 107 (3): 499–511. https://doi.org/10.1161/01.cir.0000052939.59093.45Евстифеева С. Е., Шальнова С. А., Деев А. Д., и др. Распространенность по вышенного уровня с-реактивного белка и его ассоциации с традиционными факторами риска и заболеваемостью у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014; 10 (6): 597–605. https://doi.org/10.20996/1819-6446–2014–10–6–19–23The prevalence of elevated levels of C-reactive protein and its association with traditional risk factors and morbidity among residents of the Russian Federation (according to the ESSE-RF study). Rational Pharmacotherapy in Cardiology. 2014; 10 (6): 597–605 (In Russ.) https://doi.org/10.20996/1819-6446–2014–10–6–19–23Niskanen L, Laaksonen DE, Nyyssönen K, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004; 44 (6): 859–65. https://doi.org/10.1161/01.HYP.0000146691.51307.84Niskanen L, Laaksonen DE, Nyyssönen K, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004; 44 (6): 859–65. https://doi.org/10.1161/01.HYP.0000146691.51307.84Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-Reactive Protein Con centration and Incident Hypertension in Young Adults: The CARDIA Study. Arch Intern Med. 2006; 166 (3): 345–349. https://doi.org/10.1001/archinte.166.3.345Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-Reactive Protein Con centration and Incident Hypertension in Young Adults: The CARDIA Study. Arch Intern Med. 2006; 166 (3): 345–349. https://doi.org/10.1001/archinte.166.3.345Kansui Y, Matsumura K, Morinaga Y, et al. C-reactive protein and incident hyper tension in a worksite population of Japanese men. J Clin Hypertens (Greenwich). 2019; 21 (4): 524–532. https://doi.org/10.1111/jch.13510Kansui Y, Matsumura K, Morinaga Y, et al. C-reactive protein and incident hyper tension in a worksite population of Japanese men. J Clin Hypertens (Greenwich). 2019; 21 (4): 524–532. https://doi.org/10.1111/jch.13510

The authors declare that there are no conflicts of interest present.